HighTide Therapeutics, Inc. (“HighTide”) was invited to present at the Office for Attracting Strategic Enterprises (OASES) launching ceremony hosted by the Hong Kong government. HighTide, a company focused on the discovery and development o
October 05, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, October 3rd, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that the primary findings from the Phase 2 clinical trial of berberine ursodeoxycholate (HTD1801)
October 03, 2023
Learn More
Leadership of the UK Chinese Business Association (UKCBA), including chairman, Mr. Jinlong Zhang, and secretary-general and executive vice chairman, Mr. Jie Yin, along with the UK delegation, visited HighTide Therapeutics, Inc.
July 17, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, June 24, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that data from the Phase 2a clinical trial of HTD1801, a first-in-class gut-liver anti-inflammatory metabolic modulator for patients with nonalcoholic
June 24, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, May 15, 2023— HighTide Therapeutics Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the discovery and development of first-in-class multifunctional therapies for metabolic and digestive
May 15, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, March 16, 2023— HighTide Therapeutics Inc. (“HighTide”), today announced that Dr. Liping Liu, founder and CEO of HighTide, was selected for the EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2023.
March 16, 2023
Learn More
We will contact you as soon as possible
© 2024 HighTide Therapeutics, Inc.